SCHEMBL30004272

SCHEMBL30004272

COc1c(Br)ccc(C)c1C=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.47
PRKDC P78527 1/20 0.40
AKR1B1 P15121 4/20 0.36
MAPT P10636 3/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
TUBB1 Q9H4B7 4/20 0.35
NQO2 P16083 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LCK P06239 1/20 0.33
GLA P06280 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5552745 0.81 ERN1 (0.61) ERN1PRKDCTUBB1ALDH1A1TUBB4A
SCHEMBL2007785 0.79 ERN1 (0.46) ERN1PRKDCTUBB1NQO2CA1
SCHEMBL10266008 0.79 ERN1 (0.46) ERN1PRKDCAKR1B1MAPTMEN1
SCHEMBL29712219 0.79 ERN1 (0.46) ERN1PRKDCTUBB1NQO2CA1
SCHEMBL31035587 0.79 ERN1 (0.54) ERN1PRKDCMAPTCA1CA2
SCHEMBL25290037 0.79 ERN1 (0.46) ERN1PRKDCMAPTMEN1USP2
SCHEMBL29818861 0.78 CA1 (0.47) ERN1PRKDCAKR1B1CA1CA2
SCHEMBL7055248 0.77 ERN1 (0.44) ERN1PRKDCMAPTTUBB1NQO2
SCHEMBL18300001 0.75 ERN1 (0.40) ERN1PRKDCMEN1KMT2AALDH1A1
SCHEMBL4922559 0.74 CA2 (0.44) MAPTMEN1USP2ALOX15KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4323350-A1 ISOINDOLINONE COMPOUNDS Monte Rosa Therapeutics AG (CH) 2024-02-21 EP disclosed
WO-2023069720-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed
WO-2022219407-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2022-10-20 WO disclosed